AARP Rx Watchdog Report
AARP's latest drug price study, issued Nov. 2, found prices rose 6.1% for nearly 200 of the most common brand name prescriptions during the 12 month period ending in June. The rate is slightly less than the 7.1% increase reported by AARP in 2004 (1"The Pink Sheet" April 18, 2005, p. 16). Products with the "sharpest" price increases over the first six months of 2005 included Sanofi-Aventis' Ambien 5 mg (14.4%) and Boehringer Ingelheim's Atrovent (18.6%). The Pharmaceutical Research & Manufacturers of America disputed the report, stating the Consumer Price Index price for prescription drugs increased only 3.4% for the same period...
You may also be interested in...
The prices pharmaceutical manufacturers charge wholesalers for brand name drugs have been increasing at a slower rate since the Medicare drug discount card became available, AARP concludes in an "Rx Watchdog Report" released April 12
P&G plans up to double-digit price increases in US baby care, feminine care and adult incontinence and will analyze raw material costs and foreign exchange impacts in its other product categories for other pricing changes.
Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.